secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcellx, Inc. (ACLX)
CIK:        0001786205
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000950170-25-105015
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcellx reports 97% ORR from anito-cel Phase 2; FDA clears ACLX-004 IND; Q2 net loss $52.8M
--------------------------------------------------------------------------------

- Phase 2 iMMagine-1: 97% ORR, 68% CR/sCR at 12.6 months; no delayed neurotoxicity events observed.
- FDA cleared IND for ACLX-004 (CD33/CD123) ARC-SparX platform for AML.
- Q2 2025 net loss $52.8M vs $27.2M in Q2 2024; rev $7.6M (down from $27.4M).
- Cash $537.6M expected to fund operations into 2028.
- Plan to launch anito-cel at >160 US treatment centers within first year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1786205/000095017025105015/0000950170-25-105015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1786205/000095017025105015/aclx-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-105015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer